Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations

Vicario, María; González‐Castro, Ana M; Martínez, Cristina; Lobo, Beatriz; Pigrau, Marc; Guilarte, Mar; Torres, Inés de; Mosquera, José Luis; Fortea, Marina; Sevillano-Aguilera, César; Salvo-Romero, Eloísa; Alonso, Carmen; Rodiño-Janeiro, Bruno K.; Söderholm, Johan D.; Azpiroz, Fernando; Santos, Javier

doi:10.1136/gutjnl-2013-306236

Cited by 92 publications

(85 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…activation and clinical symptoms, 34 the use of mucosal protectors constitutes a new alternative for a more efficient control of symptoms in diarrhoeapredominant IBS.…”

Section: Discussionmentioning

confidence: 99%

The combination of oligo- and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: Results of a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial

Alexea

Bacarea

Piqué

2015

United European Gastroenterology Journal

View full text Add to dashboard Cite

Background: A medical device containing the film-forming agent reticulated protein and a prebiotic mixture of vegetable oligo-and polysaccharides has been developed, recently receiving European approval as MED class III for the treatment of chronic/functional or recidivant diarrhoea due to different causes including irritable bowel syndrome (IBS). In the present paper, we evaluate a protein preparation containing these components in comparison with placebo in adult patients with diarrhoea-predominant IBS. Methods: In a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial, patients were randomly assigned to receive the combination of oligo-and polysaccharides and reticulated protein and placebo (four oral tablets/day for 56 days). Demographic, clinical and quality of life characteristics and presence and intensity of abdominal pain and flatulence (seven-point Likert scale) were assessed at three study visits (baseline and at 28 and 56 days). Stool emissions were recorded on the diary card using the seven-point Bristol Stool Scale. Results: A total of 128 patients were randomised to receive either tablets containing the combination (n ¼ 63) or placebo (n ¼ 65). Treatment with oligo-and polysaccharides and reticulated protein was safe and well tolerated. A significant improvement in symptoms across the study was observed in patients treated with oligo-and polysaccharides and reticulated protein between visit 2 and visit 3 in abdominal pain (p ¼ 0.0167) and flatulence (p ¼ 0.0373). We also detected a statistically significant increase in the quality of life of patients receiving the active treatment from baseline to visit 3 (p < 0.0001). Conclusions: Treatment with oligo-and polysaccharides and reticulated protein is safe, improving IBS symptoms and quality of life of patients with diarrhoea-predominant IBS.

show abstract

“…activation and clinical symptoms, 34 the use of mucosal protectors constitutes a new alternative for a more efficient control of symptoms in diarrhoeapredominant IBS.…”

Section: Discussionmentioning

confidence: 99%

The combination of oligo- and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: Results of a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial

Alexea

Bacarea

Piqué

2015

United European Gastroenterology Journal

View full text Add to dashboard Cite

show abstract

“…9-11 DNA microarrays have also been employed to characterize gene expression in IBS, [12][13][14] albeit somewhat less completely. Based on genes identified via microarray results, and predictive analysis of microarrays evaluation, a test utilizing a series of 32 probes representing differentially expressed genes was constructed that purportedly afforded 70% accuracy in distinguishing between mucosal tissues derived from IBS and non-IBS individuals.…”

Section: Introductionmentioning

confidence: 99%

“…Thus, a test to probe expression of IBS-relevant genes, as well as other biomarkers, may afford better discrimination between symptomatic and asymptomatic individuals, and is highly desirable. 11,13,14 Irregularities in serotonergic metabolism have also been hypothesized as potential causal factors for IBS.15 Although commonly associated with central nervous function, the majority of serotonin (95%) is synthesized within the GI tract. 16 Of this serotonin, over 90% is produced by enterochromaffin cells whereas the remainder is synthesized by neurons within the myenteric plexus.…”

mentioning

confidence: 99%

Gene Expression Profiling and Assessment of Vitamin D and Serotonin Pathway Variations in Patients With Irritable Bowel Syndrome

Dussik

Hockley

Grozić

et al. 2018

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Background/AimsIrritable bowel syndrome (IBS) is a multifaceted disorder that afflicts millions of individuals worldwide. IBS is currently diagnosed based on the presence/duration of symptoms and systematic exclusion of other conditions. A more direct manner to identify IBS is needed to reduce healthcare costs and the time required for accurate diagnosis. The overarching objective of this work is to identify gene expression-based biological signatures and biomarkers of IBS. MethodsGene transcripts from 24 tissue biopsy samples were hybridized to microarrays for gene expression profiling. A combination of multiple statistical analyses was utilized to narrow the raw microarray data to the top 200 differentially expressed genes between IBS versus control subjects. In addition, quantitative polymerase chain reaction was employed for validation of the DNA microarray data. Gene ontology/pathway enrichment analysis was performed to investigate gene expression patterns in biochemical pathways. Finally, since vitamin D has been shown to modulate serotonin production in some models, the relationship between serum vitamin D and IBS was investigated via 25-hydroxyvitamin D (25[OH]D) chemiluminescence immunoassay. ResultsA total of 858 genetic features were identified with differential expression levels between IBS and asymptomatic populations. Gene ontology enrichment analysis revealed the serotonergic pathway as most prevalent among the differentially expressed genes. Further analysis via real-time polymerase chain reaction suggested that IBS patient-derived RNA exhibited lower levels of tryptophan hydroxylase-1 expression, the enzyme that catalyzes the rate-limiting step in serotonin biosynthesis. Finally, mean values for 25(OH)D were lower in IBS patients relative to non-IBS controls. Conclusions IntroductionIrritable bowel syndrome (IBS) is one of the most common gastrointestinal (GI) disorders afflicting between 10-15% of the global population.1 Primary symptoms associated with IBS include abdominal pain and irregular bowel movements that, based upon the predominant symptom pattern, may be utilized to subdivide the syndrome into 3 classifications: diarrhea-predominant IBS (IBS-D), constipation-predominant IBS (IBS-C), and mixed IBS (IBS-M).2 However, the subtype of IBS that an individual is classified does not necessarily remain static; patients can evolve over time from diarrheic or mixed type to constipative. The chronic and erratic nature of IBS can lead to a multitude of secondary effects, such as depression, anxiety, poor quality of life, insomnia, and sexual dysfunction. 3Using the current diagnostic model for IBS, the Rome IV criteria, symptoms must be present for 3 months or longer before diagnoses can be established. 4 Other disorders with IBS-like symptoms that should be excluded include celiac disease, inflammatory bowel disease (IBD), malabsorptive disorders, pelvic floor disorders, and colon cancer. Further, once diagnosed, treatment for IBS patients may be mostly palliative in nature with dietary changes...

show abstract

“…Dentro de los mecanismos biológicos alterados se incluyen: la activación de células inmunes en la mucosa intestinal, tales como linfocitos T, linfocitos B y mastocitos; las alteraciones en la composición y aumento del número de la microbiota intestinal, que llevan al procesamiento anormal de moléculas presentes en la dieta; y la mayor liberación de sustancias bioactivas por células enterocromafines (EC) 11,14,16,17 . La respuesta inflamatoria intestinal es reforzada por una mayor actividad nerviosa entérica, relacionada al aumento de la sensibilidad visceral e incremento en la estimulación de terminales nerviosos aferentes y a la alteración del eje intestino-cerebro en estos pacientes 18 .…”

Section: Artículo Originalunclassified

Parasitosis y síndrome de intestino irritable

Ibarra

Herrera

Arce

et al. 2016

Rev. chil. infectol.

View full text Add to dashboard Cite

Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations

Abstract: Enhanced small bowel humoral immunity is a distinctive feature of IBS-D. Mucosal Ig production contributes to local inflammation and clinical manifestations in IBS-D.

Cited by 92 publications

References 45 publications

The combination of oligo- and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: Results of a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial

The combination of oligo- and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: Results of a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial

Gene Expression Profiling and Assessment of Vitamin D and Serotonin Pathway Variations in Patients With Irritable Bowel Syndrome

Parasitosis y síndrome de intestino irritable

Contact Info

Product

Resources

About